Currently Viewing
FDA Warns Against So-Called "Cancer Cure"
January 13, 2017 – Brielle Urciuoli
SPOHNC Focuses on Support for Oral, Head and Neck Cancer
January 12, 2017 – Allie Casey
Changing the Frontline Treatment of Kidney Cancer
January 12, 2017 – Gina Columbus
Chemotherapy Remains a Mainstay in Advanced Prostate Cancer
January 12, 2017 – Danielle Bucco
Expert Looks Ahead in the Treatment of MPNs
January 11, 2017 – Ellie Leick and Gina Columbus
Understanding the Language of Cancer Clinical Trials
January 11, 2017 – Allie Casey
Frontline Keytruda Gains Priority Review for Lung Cancer
January 11, 2017 – Silas Inman
Stigma and Lung Cancer
January 10, 2017 – CURE staff
Expert Discusses Targetable Mutations and New Agents in Lung Cancer
January 10, 2017 – Gina Columbus

FDA Warns Against So-Called "Cancer Cure"

The FDA recently warned consumers about PNC-27, a non-approved "treatment" for cancer. 
BY Brielle Urciuoli
PUBLISHED January 13, 2017
The US Food and Drug Administration (FDA) just added another agent, PNC-27, to the growing list of drugs that falsely claim to treat or cure cancer.

An FDA lab recently found the bacteria Variovorax paradoxus in PNC-27, a product that is claiming to treat and cure all cancers, claiming to affect lung cancer as effectively as head and neck cancer. Though no illness or serious adverse events were reported to the FDA, contact with contaminated samples can lead to life-threatening infections, especially in vulnerable populations, such as young children, elderly people, pregnant women and people who have weakened immune systems, according to a statement released by the FDA.

“In general, consumers should be cautious of products marketed and sold online claiming to treat, cure or prevent any disease. Products claiming to treat, cure or prevent disease, but are not proven safe and effective for those purposes not only defraud consumers of money, they can lead to delays in getting proper diagnosis and treatment of a potentially serious condition,” Kristofer Baumgartner, FDA spokesperson, said in an interview with CURE.

PNC-27 is being dosed in multiple ways, such as a nebulized solution, intravenous solution, vaginal suppository or rectal suppository.

The FDA is urging people not to purchase or use PNC-27, which is neither FDA evaluated or approved. Patients should consult with their licensed health care providers before deciding on a treatment plan, and if they have already taken PNC-27, they should see their doctor as soon as possible, and report any adverse events to the FDA’s MedWatch Adverse Event Reporting Program.

As a matter of policy, the FDA cannot discuss any ongoing trials in detail, Baumgartner said.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In